Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Evaluation of Overcoming Limited Migration and Enhancing Cytomegalovirus-specific Dendritic Cell Vaccines With Adjuvant TEtanus Pre-conditioning in Patients With Newly-diagnosed Glioblastoma

NCT02366728 is registered in ClinicalTrials.gov with Mustafa Khasraw, MBChB, MD, FRCP, FRACP as lead sponsor.

NCT NCT02366728
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT02366728 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Evaluation of Overcoming Limited Migration and Enhancing Cytomegalovirus-specific Dendritic Cell Vaccines With Adjuvant TEtanus Pre-conditioning in Patients With Newly-diagnosed Glioblastoma
Lead sponsor
Mustafa Khasraw, MBChB, MD, FRCP, FRACP
Phase
Phase 2
Overall status
Completed
Start date
October 12, 2015
Completion date
October 31, 2020
Enrollment
64 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

astrocytoma, grade iv, giant cell glioblastoma, glioblastoma, glioblastoma multiforme